Carisma Therapeutics Inc. Material Event - What Happened

Hey everyone, let's break down what's been going on with Carisma Therapeutics Inc. in a way that makes sense, without all the fancy finance talk. Think of this as me explaining the news to you over coffee.

---

1. What happened?

Alright, so Carisma Therapeutics Inc. just announced they are voluntarily delisting their stock from the Nasdaq stock exchange and plan to stop filing regular financial reports with the SEC. This is a significant move for any publicly traded company. On top of that, an executive, Natalie McAndrew, also resigned from her position.

In plain English, something big just happened that could change how the company operates or how its future looks. It's not just a small update; it's a pretty significant piece of news.

2. When did it happen?

This news officially broke on December 4, 2025, when the company's Board of Directors approved the voluntary delisting. The company then notified Nasdaq of its intention to file the necessary paperwork on December 5, 2025. The executive's resignation also occurred on December 5, 2025.

It's important to note that the company's stock was actually suspended from trading on Nasdaq earlier, on October 13, 2025, due to not meeting Nasdaq's listing rules.

3. Why did it happen?

To understand why this happened, we need a little background.

Carisma's stock was already suspended from Nasdaq because it didn't meet the exchange's rules. Instead of waiting for Nasdaq to formally kick them off, the company's board decided to take matters into their own hands and voluntarily delist.

When a company delists from a major exchange like Nasdaq, it often means they are facing significant financial challenges or are looking to reduce the costs and regulatory burden associated with being a publicly traded company. By also planning to stop filing regular reports with the SEC (the government body that oversees public companies), Carisma is essentially saying they no longer want to operate with the same level of public scrutiny and transparency.

The executive resignation, while not directly tied to the delisting decision, often accompanies such major corporate shifts, especially when they signal financial distress or a change in strategic direction.

4. Why does this matter?

Okay, so they did delist from Nasdaq and plan to stop SEC reporting. Why should we care?

This matters because delisting from a major exchange like Nasdaq is a very serious downgrade for a company. Nasdaq is a highly regulated and liquid market, meaning it's relatively easy to buy and sell shares. Once delisted, Carisma's stock will trade on a less regulated market called OTCID (Over-The-Counter Information and Display), which is part of the OTC Markets Group. This typically means:

• Less Transparency: There will be much less public information available about the company's financial health and operations, making it harder for investors to know what's going on.
• Lower Liquidity: It will likely be much harder to buy or sell shares, as fewer investors and brokers participate in these less regulated markets.
• Negative Signal: This move usually signals that a company is in significant financial distress or is moving towards becoming a private entity.

Essentially, this event could significantly impact Carisma's future success, its ability to develop new treatments, and ultimately, its value, primarily in a negative way for current shareholders.

5. Who is affected?

A lot of people feel the ripples from news like this:

• Investors/Shareholders: These are the people who own a piece of Carisma. Their investments are significantly impacted. Their shares will be harder to trade, less transparent, and likely face significant downward pressure on value.
• Employees: This kind of news creates a lot of uncertainty about the company's future, job security, and overall stability.
• Patients/Medical Community: While the immediate impact on drug development isn't clear, a company in financial distress may struggle to fund its research and bring new treatments to market.
• The Company Itself: Its reputation, financial health, and future strategy are all on the line. It will be much harder for them to raise money from public markets in the future.

6. What happens next?

So, what's the game plan now?

Carisma intends to file a Form 25 with the SEC around December 10, 2025, which will formally delist their stock from Nasdaq. This delisting will become effective 10 days after the filing. After that, they plan to file a Form 15 with the SEC to suspend and eventually terminate their obligations to file regular financial reports.

This means that while the stock will still be quoted on the OTCID market, there will be significantly less public information available about the company. The company will be focused on managing this transition and likely trying to navigate its financial challenges outside of the spotlight of a major stock exchange.

7. What should investors/traders know?

If you're thinking about buying or selling Carisma stock, here's what you should keep in mind:

• Extreme Risk and Volatility: The stock is already suspended from Nasdaq and moving to a much less liquid and transparent market. This is a very high-risk situation.
• Reduced Transparency: You will have significantly less information to base your investment decisions on once they stop filing with the SEC.
• Liquidity Issues: It will be much harder to buy or sell shares on the OTCID market compared to Nasdaq. You might not be able to sell your shares when you want to, or at a price you expect.
• Negative Development: This is generally considered a very negative event for a public company, indicating severe financial or operational challenges.
• Do Your Homework (if possible): Given the reduced information, any investment in Carisma at this point would be highly speculative.

This is a significant moment for Carisma Therapeutics Inc., and how it plays out will be interesting to watch, though likely from a less public vantage point.